QLT091001: Phase IIa data

A single-blind, placebo-controlled, U.S. Phase IIa trial in 43 patients ages 60-90 with early age-related macular degeneration (AMD) and impaired dark adaptation and/or impaired low luminance

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE